Capping Modification Inhibitor Development Service

Capping Modification Inhibitor Development Service

Capping Modification Inhibitor Development Service at CD BioGlyco

Two types of glycosylation are commonly considered "end-capping" modifications: fucosylation and sialylation. They are found in O-glycans, N-glycans, and glycolipids and are not further modified with other types of glycans. Based on their capping function as well as their unique structures, CD BioGlyco provides capping modification inhibitor development services.

We use a library of glycans as a starting point for high throughput screening for capping modification inhibitors. We screen the library for compounds with capping modification inhibitory effects. Examples include molecules that interfere with the fucosylation of glycans, which can interfere with the function of glycosyltransferases and thus have the effect of inhibiting fucosylation.

On the other hand, we offer the use of luciferase assay, RNA sequencing, and other techniques to test the potency of inhibitors. Cellular models are utilized to assess the selectivity of inhibitors.

Fig.1 Development content of capping modification inhibitor. (CD BioGlyco)Fig.1 Development content of capping modification inhibitor. (CD BioGlyco)


  • Capping modification inhibitors can be used in the study of a wide range of physiological activities. Examples include immune system regulation, cancer progression, angiogenesis, leukocyte adhesion, and host-microbiome interactions.
  • Capping modification is mostly fucosylation and sialylation, and the development of capping modification inhibitors can be used to probe fucosylation and desialylation on the cell surface.
  • In medicine, capping modification inhibitors can be used in anti-cancer or anti-tumor studies.


  • We provide our clients with several types of capping modification inhibitor development services, while the development process of each inhibitor includes several branches.
  • Capping modification is associated with certain physiological activities, and our capping modification inhibitor development services are expected to advance biological research.
  • We have high-quality capping modification technology to help clients solve capping modification inhibitor R&D problems.

CD BioGlyco relies on professional researchers to provide our clients with high-quality Glycosylation Inhibitor Development Services. We provide our clients with different types of inhibitors according to different types of glycosylation reactions during the development of inhibitors. We have undergone quality testing at every step to ensure our clients' satisfaction. Please feel free to contact us for more detailed information.


  1. Almahayni, K.; et al. Small molecule inhibitors of mammalian glycosylation. Matrix Biology Plus. 2022, 16: 100108.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.